source
- Kamau Therapeutics presents first clinical data from its updated sickle-cell gene-editing programKamau Therapeutics, a biotech company that entered the scene in 2023, has released clinical data from its reengineered sickle‑cell gene‑editing program for the first time. The disclosure marks the…
- AbbVie bets up to $1.47B for Nxera’s discarded IBD programAbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.BioSpace · 5d ago↗ source
- Pfizer raises 2026 outlook as oncology and migraine growth balances Covid product decline